LARIMAR THERAPEUTICS, INC. financials

LRMR CIK 0001374690

Source: EDGAR filings · Built 2026-06-02T03:28:48Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -113.29M -71.28M -33.62M -27.67M -42.44M -42.26M
EBITDA -172.15M -90.57M -41.45M -36.21M -50.14M -42.65M
Working Capital 77.23M 170.95M 80.67M 110.03M 63.36M 88.96M
Net Debt -81.34M -28.10M -21.20M -21.42M -64.09M -61.63M
Return on Equity (ROE) -212.17% -46.91% -45.21% -31.88% -78.61% -47.36%
Return on Assets (ROA) -113.60% -40.26% -38.51% -27.97% -64.37% -40.58%
Current Ratio 2.19× 8.02× 9.49× 11.28× 8.16× 10.89×
Debt-to-Equity 0.05× 0.03× 0.07× 0.05× 0.09× 0.07×
Effective Tax Rate 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Cash Conversion Ratio 0.68× 0.88× 0.91× 0.78× 0.83× 0.99×
Accruals Ratio -0.36× -0.05× -0.04× -0.06× -0.11× -0.00×
CapEx Coverage -1243.97× -137.40× -204.02× -275.69× -126.44× -680.63×
Free Cash Flow Per Share $-1.16 $-0.77 $-1.07 $-2.47 $-3.56

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/B 4.05× 1.44× 2.44× 1.61× 2.97× 3.67×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Research and Development Expense 154.22M 73.28M 27.67M 24.25M 38.40M 31.41M
Operating Expenses 172.50M 90.89M 41.76M 36.53M 50.47M 42.80M
Operating Income (Loss) -172.50M -90.89M -41.76M -36.53M -50.47M -42.80M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -165.67M -80.60M -36.95M -35.35M -50.64M -42.48M
Earnings Per Share, Basic $-1.32 $-0.84 $-1.37 $-2.95 $-3.57
Weighted Average Number of Shares Outstanding, Basic 61.26M 43.90M 25.76M 17.16M 11.88M
Earnings Per Share, Diluted $-1.32 $-0.84 $-1.37 $-2.95 $-3.57
Weighted Average Number of Shares Outstanding, Diluted 61.26M 43.90M 25.76M 17.16M 11.88M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 85.41M 33.22M 26.75M 26.82M 70.10M 68.15M
Assets, Current 142.02M 195.30M 90.17M 120.74M 72.20M 97.95M
Assets 145.84M 200.22M 95.94M 126.41M 78.67M 104.69M
Liabilities, Current 64.80M 24.36M 9.51M 10.71M 8.85M 8.99M
Liabilities 67.76M 28.41M 14.21M 15.50M 14.25M 14.99M
Stockholders' Equity Attributable to Parent 78.08M 171.81M 81.72M 110.90M 64.41M 89.69M
Common Stock, Shares, Outstanding 83.09M 63.82M 43.91M 43.27M 17.71M 15.37M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -113.20M -70.76M -33.46M -27.57M -42.10M -42.20M
Payments to Acquire Property, Plant, and Equipment 91.00K 515.00K 164.00K 100.00K 333.00K 62.00K
Net Cash Provided by (Used in) Investing Activities 100.31M -85.39M 33.35M -90.96M 24.17M 17.09M
Net Cash Provided by (Used in) Financing Activities 65.09M 161.88M 30.00K 75.26M 19.89M 93.59M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (LRMR CIK 0001374690), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

BX

Blackstone Inc.

KALV

KalVista Pharmaceuticals, Inc.

SLM

SLM Corp